JP2024514026A - 哺乳類の樹状細胞の過剰活性化因子 - Google Patents
哺乳類の樹状細胞の過剰活性化因子 Download PDFInfo
- Publication number
- JP2024514026A JP2024514026A JP2024506588A JP2024506588A JP2024514026A JP 2024514026 A JP2024514026 A JP 2024514026A JP 2024506588 A JP2024506588 A JP 2024506588A JP 2024506588 A JP2024506588 A JP 2024506588A JP 2024514026 A JP2024514026 A JP 2024514026A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- lpc
- acyl chain
- agonist
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163173958P | 2021-04-12 | 2021-04-12 | |
| US63/173,958 | 2021-04-12 | ||
| US202163246740P | 2021-09-21 | 2021-09-21 | |
| US63/246,740 | 2021-09-21 | ||
| PCT/US2022/071664 WO2022221827A2 (en) | 2021-04-12 | 2022-04-11 | Hyperactivators of mammalian dendritic cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514026A true JP2024514026A (ja) | 2024-03-27 |
| JP2024514026A5 JP2024514026A5 (cg-RX-API-DMAC7.html) | 2025-04-21 |
Family
ID=81749254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506588A Pending JP2024514026A (ja) | 2021-04-12 | 2022-04-11 | 哺乳類の樹状細胞の過剰活性化因子 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240197869A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4322999A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514026A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022257111A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3215072A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307508A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022221827A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4475824A1 (en) * | 2022-02-07 | 2024-12-18 | Corner Therapeutics, Inc. | Immunogenic mrna delivery vehicles |
| US20250127868A1 (en) * | 2022-02-07 | 2025-04-24 | Corner Therapeutics, Inc. | Hyperactivating lipid nanoparticles |
| EP4654955A2 (en) * | 2023-01-27 | 2025-12-03 | Corner Therapeutics, Inc. | Phospholipid analogs for hyperactivation of mammalian dendritic cells |
| WO2024192034A2 (en) * | 2023-03-13 | 2024-09-19 | Corner Therapeutics, Inc. | Bystander antigen enhancement of tumor cell lysate immunogenicity |
| WO2025221606A1 (en) * | 2024-04-16 | 2025-10-23 | Corner Therapeutics, Inc. | Lipids for hyperactivation of mammalian dendritic cells |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005530488A (ja) * | 2002-03-11 | 2005-10-13 | ベーイーオー・メリュー | invitroで単球を成熟樹状細胞に分化させるためのL−α−リゾホスファチジルコリンの使用 |
| JP2016518313A (ja) * | 2013-03-12 | 2016-06-23 | アリビオ, インコーポレーテッド | リゾホスファチジルコリン又はその誘導体を含む脂質ナノ物質、及びその製造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2836828A1 (fr) * | 2002-03-11 | 2003-09-12 | Bio Merieux | Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro |
| WO2004091603A1 (fr) * | 2003-04-07 | 2004-10-28 | Clinigenetics | Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires |
| CN102293743B (zh) * | 2010-06-24 | 2013-09-18 | 辽宁成大生物股份有限公司 | 一种脂质微球组合物 |
-
2022
- 2022-04-11 JP JP2024506588A patent/JP2024514026A/ja active Pending
- 2022-04-11 IL IL307508A patent/IL307508A/en unknown
- 2022-04-11 WO PCT/US2022/071664 patent/WO2022221827A2/en not_active Ceased
- 2022-04-11 US US18/286,333 patent/US20240197869A1/en active Pending
- 2022-04-11 CA CA3215072A patent/CA3215072A1/en active Pending
- 2022-04-11 AU AU2022257111A patent/AU2022257111A1/en active Pending
- 2022-04-11 EP EP22724603.0A patent/EP4322999A2/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005530488A (ja) * | 2002-03-11 | 2005-10-13 | ベーイーオー・メリュー | invitroで単球を成熟樹状細胞に分化させるためのL−α−リゾホスファチジルコリンの使用 |
| JP2016518313A (ja) * | 2013-03-12 | 2016-06-23 | アリビオ, インコーポレーテッド | リゾホスファチジルコリン又はその誘導体を含む脂質ナノ物質、及びその製造方法 |
Non-Patent Citations (3)
| Title |
|---|
| J OF IMMUNOLOGY, vol. 169, JPN6026024416, 2002, pages 1688 - 1695, ISSN: 0005883335 * |
| PROSTAGLANDINS OTHER LIPID MEDIAT, vol. Vol.89, No.3-4, JPN6026024415, 2009, pages 73 - 81, ISSN: 0005883334 * |
| VACCINE, vol. 34, no. 36, JPN6026024414, 2016, pages 4304 - 4312, ISSN: 0005883333 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022221827A3 (en) | 2022-12-29 |
| EP4322999A2 (en) | 2024-02-21 |
| US20240197869A1 (en) | 2024-06-20 |
| WO2022221827A2 (en) | 2022-10-20 |
| IL307508A (en) | 2023-12-01 |
| CA3215072A1 (en) | 2022-10-20 |
| AU2022257111A1 (en) | 2023-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240197869A1 (en) | Hyperactivators of mammalian dendritic cells | |
| US12258581B2 (en) | T cell manufacturing compositions and methods | |
| JP2021181462A (ja) | ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物 | |
| US10597731B2 (en) | Allogeneic autophagosome-enriched composition for the treatment of disease | |
| TW202402303A (zh) | 編碼具持續性活性之環GMP-AMP合成酶之mRNA及用於彼等之脂質遞送載體 | |
| US20250127868A1 (en) | Hyperactivating lipid nanoparticles | |
| TW202345909A (zh) | 免疫原性mRNA遞送載體 | |
| CN118215501A (zh) | 哺乳动物树突细胞的超激活剂 | |
| CN118922179A (zh) | 超激活脂质纳米颗粒 | |
| TW202400253A (zh) | 編碼具持續性活性之環gmp-amp合成酶之核酸及用於彼等之免疫原性遞送載體 | |
| EP4654955A2 (en) | Phospholipid analogs for hyperactivation of mammalian dendritic cells | |
| TW202502377A (zh) | 旁觀者抗原增強之腫瘤細胞溶解物免疫原性 | |
| WO2025221606A1 (en) | Lipids for hyperactivation of mammalian dendritic cells | |
| WO2025221993A1 (en) | Compositions and methods for producing il-16 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250411 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250411 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260611 |